SCHEMBL6154619

SCHEMBL6154619

COc1cc(NC2CCC(NC(C)C)CC2)c(Cl)cc1C(N)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.44
LRRK2 Q5S007 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA3 P07451 1/20 0.44
CA6 P23280 1/20 0.44
CA7 P43166 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
HSP90AA1 P07900 1/20 0.42
RIPK2 O43353 1/20 0.42
ERN1 O75460 1/20 0.42
STK10 O94804 1/20 0.42
MAP3K6 O95382 1/20 0.42
ABL1 P00519 1/20 0.42
ESR1 P03372 1/20 0.42
RET P07949 1/20 0.42
PDGFRB P09619 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
KIT P10721 1/20 0.42
BCR P11274 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154617 1.00 HTT (0.44) HTTLRRK2CA1CA2CA3
SCHEMBL12316370 0.89 CA1 (0.51) LRRK2CA1CA2CA3CA6
SCHEMBL6153305 0.87 CA1 (0.47) LRRK2CA1CA2CA3CA6
SCHEMBL6153343 0.87 CA1 (0.47) LRRK2CA1CA2CA3CA6
SCHEMBL6153479 0.87 ROCK2 (0.52) HTTLRRK2CA1CA2CA3
SCHEMBL6154397 0.87 LRRK2 (0.49) HTTLRRK2CA1CA2CA3
SCHEMBL6153878 0.87 ROCK2 (0.52) HTTLRRK2CA1CA2CA3
SCHEMBL6153477 0.87 ROCK2 (0.52) HTTLRRK2CA1CA2CA3
SCHEMBL6154410 0.87 LRRK2 (0.49) HTTLRRK2CA1CA2CA3
SCHEMBL6156118 0.84 LRRK2 (0.44) HTTLRRK2CA1CA2CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US claimed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP claimed
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 HTT 3934/4885LRRK2 3177/4885CA1 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.